Assembly Biosciences PE Ratio 2010-2024 | ASMB
Current and historical p/e ratio for Assembly Biosciences (ASMB) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Assembly Biosciences PE ratio as of January 23, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Assembly Biosciences PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2025-01-23 |
14.87 |
|
0.00 |
| 2024-09-30 |
15.14 |
$-5.15 |
0.00 |
| 2024-06-30 |
13.72 |
$-6.88 |
0.00 |
| 2024-03-31 |
13.30 |
$-8.74 |
0.00 |
| 2023-12-31 |
9.84 |
$-11.52 |
0.00 |
| 2023-09-30 |
10.62 |
$-17.05 |
0.00 |
| 2023-06-30 |
13.80 |
$-19.57 |
0.00 |
| 2023-03-31 |
10.08 |
$-21.85 |
0.00 |
| 2022-12-31 |
15.60 |
$-23.17 |
0.00 |
| 2022-09-30 |
19.68 |
$-34.09 |
0.00 |
| 2022-06-30 |
25.20 |
$-33.25 |
0.00 |
| 2022-03-31 |
24.72 |
$-33.73 |
0.00 |
| 2021-12-31 |
27.96 |
$-36.25 |
0.00 |
| 2021-09-30 |
41.76 |
$-33.13 |
0.00 |
| 2021-06-30 |
46.56 |
$-29.29 |
0.00 |
| 2021-03-31 |
55.20 |
$-20.41 |
0.00 |
| 2020-12-31 |
72.60 |
$-21.25 |
0.00 |
| 2020-09-30 |
197.28 |
$-19.81 |
0.00 |
| 2020-06-30 |
279.84 |
$-30.25 |
0.00 |
| 2020-03-31 |
177.96 |
$-41.18 |
0.00 |
| 2019-12-31 |
245.52 |
$-44.66 |
0.00 |
| 2019-09-30 |
117.96 |
$-45.14 |
0.00 |
| 2019-06-30 |
161.88 |
$-44.06 |
0.00 |
| 2019-03-31 |
236.28 |
$-51.02 |
0.00 |
| 2018-12-31 |
271.44 |
$-48.02 |
0.00 |
| 2018-09-30 |
445.68 |
$-37.57 |
0.00 |
| 2018-06-30 |
470.52 |
$-35.65 |
0.00 |
| 2018-03-31 |
589.68 |
$-29.41 |
0.00 |
| 2017-12-31 |
543.00 |
$-29.53 |
0.00 |
| 2017-09-30 |
419.04 |
$-35.65 |
0.00 |
| 2017-06-30 |
247.80 |
$-35.17 |
0.00 |
| 2017-03-31 |
305.88 |
$-32.89 |
0.00 |
| 2016-12-31 |
145.80 |
$-30.85 |
0.00 |
| 2016-09-30 |
86.52 |
$-28.21 |
0.00 |
| 2016-06-30 |
66.60 |
$-24.73 |
0.00 |
| 2016-03-31 |
60.24 |
$-22.57 |
0.00 |
| 2015-12-31 |
90.12 |
$-22.57 |
0.00 |
| 2015-09-30 |
114.72 |
$-21.73 |
0.00 |
| 2015-06-30 |
231.12 |
$-33.13 |
0.00 |
| 2015-03-31 |
158.88 |
$-34.45 |
0.00 |
| 2014-12-31 |
94.32 |
$-26.77 |
0.00 |
| 2014-09-30 |
98.28 |
$-22.21 |
0.00 |
| 2014-06-30 |
78.60 |
$-6.24 |
0.00 |
| 2014-03-31 |
76.50 |
$-14.41 |
0.00 |
| 2013-12-31 |
229.20 |
$-27.61 |
0.00 |
| 2013-09-30 |
173.40 |
$-27.61 |
0.00 |
| 2013-06-30 |
144.00 |
$-52.22 |
0.00 |
| 2013-03-31 |
179.40 |
$-73.23 |
0.00 |
| 2012-12-31 |
129.60 |
$-99.64 |
0.00 |
| 2012-09-30 |
214.80 |
$-99.64 |
0.00 |
| 2012-06-30 |
256.20 |
$-105.04 |
0.00 |
| 2012-03-31 |
598.20 |
$-355.34 |
0.00 |
| 2011-12-31 |
480.48 |
$-338.54 |
0.00 |
| 2011-09-30 |
541.80 |
$-338.54 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.095B |
$0.007B |
|
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
|
